Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,028,222

« Back to Dashboard
Patent 6,028,222 protects OFIRMEV and is included in one NDA. There has been one Paragraph IV challenge on Ofirmev.

Protection for OFIRMEV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-nine patent family members in twenty-one countries.

Summary for Patent: 6,028,222

Title: Stable liquid paracetamol compositions, and method for preparing same
Abstract:Novel stable paracetamol compositions for use in therapeutic chemistry and specifically galenic pharmacy are disclosed. The compositions contain a solution of paracetamol in an aqueous solvent combined with a buffer having a pH of 4 to 8, and a free radical capturing agent. A water-insoluble inert gas is carefully bubbled through the aqueous solvent to remove oxygen from the medium. Said compositions may also be combined with a centrally or peripherally acting analgesic agent, and are provided as injectable compositions for relieving pain.
Inventor(s): Dietlin; Francois (Le Pecq, FR), Fredj; Daniele (Gif-sur-Yvette, FR)
Assignee: SCR Pharmatop (FR)
Application Number:09/051,246
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 4th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mallinckrodt Ip
SOLUTION;IV (INFUSION)022450-001Nov 2, 2010RXYes6,028,222*PEDFeb 5, 2018Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,028,222

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France96 09858Aug 05, 1996
France96 09858Aug 5, 1996
PCT Information
PCT FiledAugust 05, 1997PCT Application Number:PCT/FR97/01452
PCT Publication Date:February 12, 1998PCT Publication Number: WO98/05314

International Patent Family for Patent: 6,028,222

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark0858329► subscribe
European Patent Office0858329► subscribe
Spain2201316► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.